15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Tonix Pharmaceuticals Holding Corp, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $22.00 to $26.00, so the covering firms are broadly aligned. The average target of $24.00 sits 142% above the current $9.93. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.41 next quarter toward $-7.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy150%
Buy150%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Tonix Pharmaceuticals Holding Corp.
As of Jul, 2 of 2 firms rate TNXP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TNXP EPS & revenue forecast
EPS · NEXT QUARTER
$-2.41
Range $-2.53 – $-2.29 · 2 analysts · -35% YoY
Next period, 2 analysts expect Tonix Pharmaceuticals Holding Corp to earn $-2.41 a share (range $-2.53 – $-2.29), versus $-3.70 a year earlier. Full-year consensus is $-10.10, growing to $-7.80 the year after.
REVENUE · NEXT QUARTER
$9.2M
Range $7.8M – $13.0M · 2 analysts · +181% YoY
Revenue is expected to reach $9.2M (range $7.8M – $13.0M), +180.7% year-over-year. Full-year consensus is $34.2M, rising to $78.9M next year.
Top analysts covering Tonix Pharmaceuticals Holding Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TNXP.
#1
TF
Tiago Fauth
Raymond James
Buy
$26.00+161.8% to target
Coverage
—
+ Follow
#2
SK
Stacy Ku
TD Cowen
Buy
$22.00+121.6% to target
Coverage
—
+ Follow
#3
RL
Robert LeBoyer
Noble Financial
Buy
$37.00+272.6% to target
Coverage
—
+ Follow
TNXP stock forecast FAQ
What is TNXP's average 12-month price target?+
The 2 analysts with a live target average $24.00 for Tonix Pharmaceuticals Holding Corp over the next 12 months, ranging from a $26.00 high to a $22.00 low.
Is TNXP stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TNXP?+
The Street-high target is $26.00 (Raymond James), and the Street-low is $22.00 (TD Cowen). The average of all 2 active targets is $24.00.
How many Wall Street analysts cover TNXP?+
2 analysts have an active rating on Tonix Pharmaceuticals Holding Corp, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering TNXP?+
Among analysts who currently cover TNXP, Tiago Fauth of Raymond James has the strongest overall Quantellect track record. Their current call is Buy with a $26.00 target.
What is Tonix Pharmaceuticals Holding Corp's projected EPS for next quarter?+
The consensus estimate is $-2.41 per share (range $-2.53 – $-2.29) across 2 analysts. Full-year EPS is projected at $-10.10, rising to $-7.80 the following year.
How much revenue is Tonix Pharmaceuticals Holding Corp expected to report next quarter?+
Consensus revenue is $9.2M (range $7.8M – $13.0M). Full-year revenue is projected at $34.2M, growing to $78.9M next year.
Have analysts been upgrading or downgrading TNXP lately?+
As of Jul, 2 of 2 firms rate TNXP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TNXP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
